Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today s conference is being recorded.
Earnings call: PolyPid s Q3 2023 financial results show decreased expenses and progress in SHIELD II trial By Investing com investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.
H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ: ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.